2. Search Result
Search Result
Results for "

GI injury

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10182
    Laduviglusib
    Maximum Cited Publications
    218 Publications Verification

    CHIR-99021; CT99021

    		 Organoid GSK-3 Wnt β-catenin Autophagy Metabolic Disease Cancer
    Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
    Laduviglusib
  • HY-10182R
    Laduviglusib (Standard)

    CHIR-99021 (Standard); CT99021 (Standard)

    		 Organoid GSK-3 Autophagy Wnt β-catenin Reference Standards Cancer
    Laduviglusib (Standard) is the analytical standard of Laduviglusib. Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
    Laduviglusib (Standard)
  • HY-10182G
    Laduviglusib
    1 Publications Verification

    CHIR-99021; CT99021

    		 GSK-3 Wnt β-catenin Autophagy Metabolic Disease Cancer
    Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.
    Laduviglusib
  • HY-B0194
    Tizanidine

    		Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Tizanidine is an orally active, imidazoline central α2-adrenoceptor agonist (IC50 = 6.9 nmol), which can be used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI). Tizanidine is a centrally acting skeletal muscle relaxant. Tizanidine reduces the release of the excitatory amino acids glutamate and aspartate from the presynaptic terminal of spinal interneurons. Tizanidine reduces tonic stretch reflexes and polysynaptic reflex activity in spinal transected cat model. Tizanidine can decrease blood pressure and heart rate in animal models. Tizanidine possesses antinociceptive activity and inhibits gastrointestinal (GI) transit .
    Tizanidine
  • HY-10182C
    Laduviglusib dihydrochloride

    CHIR-99021 dihydrochloride; CT99021 dihydrochloride

    		 GSK-3 β-catenin Wnt Metabolic Disease Cancer
    Laduviglusib;CHIR 99021;CHIR99021;CHIR-99021;CT99021;CT 99021;CT-99021
    Laduviglusib dihydrochloride
  • HY-B0194R
    Tizanidine (Standard)

    		Reference Standards Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Tizanidine (Standard) is the analytical standard of Tizanidine. This product is intended for research and analytical applications. Tizanidine is an orally active, imidazoline central α2-adrenoceptor agonist (IC50 = 6.9 nmol), which can be used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI). Tizanidine is a centrally acting skeletal muscle relaxant. Tizanidine reduces the release of the excitatory amino acids glutamate and aspartate from the presynaptic terminal of spinal interneurons. Tizanidine reduces tonic stretch reflexes and polysynaptic reflex activity in spinal transected cat model. Tizanidine can decrease blood pressure and heart rate in animal models. Tizanidine possesses antinociceptive activity and inhibits gastrointestinal (GI) transit .
    Tizanidine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: